Post-marketing surveillance for acute Kawasaki Disease under Remicade treatment
Not Applicable
- Conditions
- Acute Kawasaki disease
- Registration Number
- JPRN-UMIN000025429
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Brief Summary
Please see: https://journals.lww.com/pidj/Fulltext/2020/01000/Real_world_Safety_and_Effectiveness_of_Infliximab.8.aspx
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 291
Inclusion Criteria
Not provided
Exclusion Criteria
Patients with acute Kawasaki disease who meet "CONTRAINDICATIONS" to the use of the Drug
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method